Cellivia

Executive Summary

Cellivia, founded in 2018 and headquartered in Warsaw, Poland, is a biotechnology company operating a specialized tissue and cell bank. The company collects and cryopreserves oral-derived tissues, such as dental pulp and gum, obtained during routine dental procedures. Its core mission is to enable future access to personalized regenerative medicine and advanced therapies by preserving patients' own biological materials. By focusing on easily obtainable oral tissues, Cellivia aims to lower the barrier for individuals to store their cells for potential future therapeutic use, positioning itself at the intersection of dentistry and regenerative medicine. Cellivia's business model leverages the growing interest in biobanking and personalized medicine, yet the company faces significant challenges, including regulatory hurdles, public awareness, and the need for clinical validation of stored tissue utility. As a private company with no disclosed funding or revenue, its trajectory remains uncertain. However, the increasing demand for stem cell-based therapies and the non-invasive nature of dental tissue collection provide a promising niche. If successful, Cellivia could become a key player in Eastern Europe's biobanking sector.

Upcoming Catalysts (preview)

• Q3 2026Regulatory accreditation from Polish Ministry of Health for tissue bank operations60% success
• Q4 2026Partnership with national dental clinic network to expand tissue collection50% success
• TBDFirst revenue generation from stored tissue release for research or therapy30% success